PriceTracker GLP-1
Loading the index…

Try

Find the cheapest for me

What happened

Retatrutide is Lilly's experimental once-weekly injection that acts on three hormone receptors (GIP, GLP-1 and glucagon). Through 2026 Lilly has reported a run of phase 3 results, and the most recent, on October 28, 2026, put it head to head against Ozempic for the first time.

TRIUMPH-1 (May 21, 2026) enrolled 2,339 adults with obesity or overweight and no diabetes for 80 weeks. On the highest dose, people lost an average of 28.3% of their body weight (70.3 lb) if they stayed on treatment, against 2.2% on placebo; 45.3% lost 30% or more. Counting everyone who started, the highest dose averaged 25.0% against 3.9%. In a 104-week extension for people with a BMI of 35 or higher, weight loss reached up to 30.3%.

TRIUMPH-2 (detailed results Sep 29, 2026) tested adults with obesity and type 2 diabetes: 20.8% average weight loss on the highest dose at 80 weeks. TRANSCEND-T2D-2 (Oct 28, 2026) found weight loss of 20% to 21% on retatrutide against 9% on Ozempic at its highest approved dose after 80 weeks, with A1C down 2.2 points against 1.8.

The most common side effects in TRIUMPH-1 were stomach and gut effects: on the highest dose, nausea in 42.4% against 14.8% on placebo and vomiting in 25.3% against 4.8%. Dysesthesia (an altered skin sensation) was reported in 12.5% against 0.9%. Lilly says retatrutide "is an investigational molecule that is legally available only to participants in Lilly's clinical trials."

What this means for cost

Retatrutide has no price: it is not approved, and anything sold online as retatrutide today is not Lilly's drug. The approved medicines closest to it are tirzepatide and semaglutide. These are today's prices, from the makers' self-pay pages and the dated reads on our board.

Compounded drugs are not FDA-approved.

What happens next

  • Q1 2027Lilly plans to submit retatrutide to the FDA for US approval (a Biologics License Application).
  • After filingFDA review. Lilly has not given a decision date; we will add it when one is published.

Sources

  1. Eli Lilly, TRIUMPH-1 topline results (May 21, 2026), read 20 Nov 2026
  2. Eli Lilly, TRIUMPH-2 and TRIUMPH-3 topline results and Q1 2027 filing plan (Jul 23, 2026), read 20 Nov 2026
  3. Eli Lilly, TRIUMPH-2 detailed results (Sep 29, 2026), read 20 Nov 2026
  4. Eli Lilly press releases, including TRANSCEND-T2D-2 (Oct 28, 2026), read 20 Nov 2026

Read next